Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Hepatitis C/co-infection with HIV Stories

2012-05-11 23:00:43

New Center Tailored to Treat Rising Population for “Silent Killer” Philadelphia, PA (PRWEB) May 11, 2012 Thomas Jefferson University Hospital recently opened its new Jefferson Hepatitis C Center, one of only a few comprehensive, multidisciplinary centers dedicated to the study of hepatitis C virus and hepatic disease in the Pennsylvania, New Jersey and Delaware tri-state area. According to the Centers for Disease Control and Prevention (CDC), 3.2 million Americans are infected...

2012-05-08 06:30:53

SAN DIEGO, May 8, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the presence of Hepatitis C virus (HCV) is currently undetectable in all infected patients that have been treated with the Aethlon Hemopurifier® in combination with peginterferon+ribavirin (PR) drug therapy and monitored for at least ninety days....

2012-05-01 21:32:14

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression. In a review article, researchers tackle the complexities of diagnosing and managing depression before and after initiating treatment with interferon. Dr. Murali S. Rao of Loyola University Medical Center is a co-author of the study, published in the International Journal of Interferon, Cytokine and Mediator Research....

2012-04-25 06:24:52

BIRMINGHAM, Ala., April 25, 2012 /PRNewswire-USNewswire/ -- Southern Research today announced that it has signed an agreement with Apath, LLC which will allow Southern Research to conduct laboratory testing, research, and/or screening of potential therapeutic agents for hepatitis C (HCV) on an exclusive, fee-for-service basis using Apath's HCV virus-based technology. Apath--a privately held technology company focusing on HCV and other human viral pathogens--was founded by Charles M. Rice,...

2012-04-24 06:26:09

SAN DIEGO, April 24, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) The gold standard for determining drug therapy benefit against infectious disease targets is to measure changes in patient viral load, otherwise known as the amount of virus that is detectable in circulation. Specific to Hepatitis C virus (HCV), the best...

2012-04-19 19:59:25

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects. The following new studies cover the treatment of HCV patients with genotypes (GT) 1, 2 or 3, who were administered ribavirin (RBV) - without IFN - and either one or two other...

2012-04-19 19:55:06

Additional data provides hope for HCV non-responders New data from a number of clinical trials presented for the first time at the International Liver Congress 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations. In the first multicentric study of the efficacy and safety of the protease inhibitors (PI) Boceprevir or Telaprevir in patients with severe HCV genotype 1 (GT1) recurrence after liver transplantation, results show that 57% of patients...

2012-04-19 02:29:25

BARCELONA, April 19, 2012 /PRNewswire/ - Today Merck announced results demonstrating no difference in the rates of viral clearance between two anemia management strategies for patients with chronic hepatitis C virus (HVC) genotype 1 infection treated with VICTRELIS(TM) (boceprevir) in combination with peginterferon alfa-2b and ribavirin (P/R). Anemia is a common development of P/R therapy for chronic hepatitis C patients. For the patients studied, the anemia was either managed by...

2012-04-04 06:27:17

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress(TM) 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral...

2012-04-04 06:26:54

BEERSE, Belgium, April 4, 2012 /PRNewswire/ -- Not Intended for US Journalists - Analysis to be presented at European Association for the Study of the Liver (EASL) 2012 shows clinical and cost-effectiveness regardless of IL28B subtype - Janssen Pharmaceutica NV (Janssen) will present a cost-effectiveness analysis for INCIVO(telaprevir) at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The analysis...


Latest Hepatitis C/co-infection with HIV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »